Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Amgen returns epratuzumab rights to Immunomedics

April 15, 2004

Financing at Favrille supports phase II and phase III trials

April 14, 2004

ZymoGenetics cleared to commence phase I study of IL-21

April 7, 2004

Improvement in survival indicated in phase IIb trial of L-BLP-25

April 7, 2004

Promising initial clinical results for HYB-2055 presented in Orlando

April 6, 2004

AMD-3100 enters fifth phase II trial for stem cell transplantation

April 6, 2004

Canvaxin reported to improve survival of patients with early stage melanoma

April 6, 2004

Immunotherapy with antigen presenting cells for metastatic breast and prostate cancer

April 6, 2004

Monoclonal antibody effective against cancer progression in vivo

April 5, 2004

WX-G250 plus IFNalpha-2a reported safe and effective in renal cell carcinoma

April 2, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.